TABLE 9.
Nature and incidence of treatment-related laboratory abnormalities in comparative studies
| Parameter | Fluconazole
|
Oral polyenes
|
Ketoconazole
|
|||
|---|---|---|---|---|---|---|
| No. of patients tested | No. (%) of patients with abnormalitiesa | No. of patients tested | No. (%) of patients with abnormalitiesa | No. of patients tested | No. (%) of patients with abnormalitiesa | |
| Hematology | ||||||
| Hemoglobin concn | 373 | 2 (0.5) | 343 | 1 (0.3) | 23 | 0 |
| Leukocyte count | 375 | 0 | 344 | 0 | 25 | 1 (4.0) |
| Neutrophil count | 320 | 0 | 302 | 0 | 20 | 0 |
| Eosinophil count | 324 | 4 (1.2) | 308 | 2 (0.6) | 19 | 0 |
| Platelet count | 372 | 4 (1.1) | 342 | 0 | 24 | 0 |
| Hepatic function | ||||||
| AST (SGOTb) level | 333 | 8 (2.4) | 309 | 10 (3.2) | 20 | 1 (5.0) |
| ALT (SGPTc) level | 316 | 18 (5.7) | 289 | 17 (5.9) | 19 | 2 (10.5) |
| Alkaline phosphatase level | 291 | 8 (2.7) | 274 | 3 (1.1) | 14 | 0 |
| Total bilirubin concn | 284 | 3 (1.1) | 276 | 4 (1.4) | 13 | 0 |
| Renal function | ||||||
| Blood urea nitrogen concn | 88 | 0 | 83 | 0 | 0 | 0 |
| Creatinine concn | 357 | 0 | 324 | 0 | 15 | 0 |
a
Laboratory abnormalities were not necessarily reported as side effects.
b
SGOT, serum glutamic oxalacetic transaminase.
c
SGPT, serum glutamic pyruvic transaminase.